Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; Integrated Biomedical Sciences Program, Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Department of Immunology, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.
Mol Ther Methods Clin Dev. 2016 Jan 27;3:15054. doi: 10.1038/mtm.2015.54. eCollection 2016.
Transgenic expression of antigen-specific T-cell receptor (TCR) genes is a promising approach for immunotherapy against infectious diseases and cancers. A key to the efficient application of this approach is the rapid and specific isolation and cloning of TCRs. Current methods are often labor-intensive, nonspecific, and/or relatively slow. Here, we describe an efficient system for antigen-specific αβTCR cloning and CDR3 substitution. We demonstrate the capability of cloning influenza-specific TCRs within 10 days using single-cell polymerase chain reaction (PCR) and Gibson Assembly techniques. This process can be accelerated to 5 days by generating receptor libraries, requiring only the exchange of the antigen-specific CDR3 region into an existing backbone. We describe the construction of this library for human γδ TCRs and report the cloning and expression of a TRGV9/TRDV2 receptor that is activated by zoledronic acid. The functional activity of these αβ and γδ TCRs can be characterized in a novel reporter cell line (Nur77-GFP Jurkat 76 TCRα(-)β(-)) for screening of TCR specificity and avidity. In summary, we provide a rapid method for the cloning, expression, and functional characterization of human and mouse TCRs that can assist in the development of TCR-mediated therapeutics.
转基因表达抗原特异性 T 细胞受体 (TCR) 基因是一种有前途的传染病和癌症免疫治疗方法。这种方法的有效应用的关键是 TCR 的快速和特异性分离和克隆。目前的方法往往劳动强度大、非特异性和/或相对较慢。在这里,我们描述了一种用于抗原特异性 αβTCR 克隆和 CDR3 替换的有效系统。我们通过使用单细胞聚合酶链反应 (PCR) 和 Gibson 组装技术,在 10 天内展示了克隆流感特异性 TCR 的能力。通过生成受体文库,将抗原特异性 CDR3 区域交换到现有骨架中,这个过程可以加速到 5 天。我们描述了这种人类 γδTCR 文库的构建,并报告了由唑来膦酸激活的 TRGV9/TRDV2 受体的克隆和表达。这些 αβ 和 γδTCR 的功能活性可以在新型报告细胞系(Nur77-GFP Jurkat 76 TCRα(-)β(-))中进行表征,用于筛选 TCR 特异性和亲和力。总之,我们提供了一种快速克隆、表达和功能表征人类和小鼠 TCR 的方法,可用于 TCR 介导的治疗药物的开发。